Mateus Trinconi: Extracted individual patient data meta-analysis on EFS and OS in neoadj IO in stage II-III TNBC
Mateus Trinconi, Medical Oncology Fellow at University of Toronto, shared a post on X/Twitter:
“Proud to share this extracted individual patient data meta-analysis on EFS and OS in neoadj IO in stage II-III TNBC. Only possible with this stellar team!
Included RCTs were KN522, IMpassion031, GeparNuevo, and I-SPY 2. EFS HR was 0.61 (0.49-0.76), and NNT to avoid one event was 9. We conducted a leave-one-out analysis and the effect is still significant after excluding KN522, with HR 0.62 (0.43-0.88).
OS analysis included KN522, IM032, and GNuevo, and, although proportional hazards assumption was broken, the difference between arms was significant with RMST.
Expl. analysis of EFS stratified by pCR achievement showed improved survival in those who achieve pCR regardless of treatment arm. There was a trend towards benefit of neoadj IO in both complete responders and non-complete responders.”
For details click here
Source: Mateus Trinconi/Twitter
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023